Linezolid Kabi

Linezolid, the active ingredient in Linezolid Kabi, is an oxazolidinone presented as an injection solution for intravenous use. It treats serious bacterial infections such as skin and soft‑tissue infections, community‑acquired pneumonia, hospital‑acquired pneumonia, methicillin‑resistant Staphylococcus aureus (MRSA) and vancomycin‑resistant Enterococcus (VRE) in adult patients.

GNH USA supplies Linezolid Kabi as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Linezolid is an oxazolidinone antibacterial indicated for several serious infections.

- Skin and soft tissue infections: effective against Gram‑positive pathogens, reducing lesion size and bacterial load. - Community‑acquired pneumonia: improves clinical cure rates in adult patients with typical and atypical organisms. - Hospital‑acquired (nosocomial) pneumonia: provides coverage for resistant strains in intensive‑care settings. - Methicillin‑resistant Staphylococcus aureus (MRSA) infections: offers an alternative when beta‑lactams are ineffective. - Vancomycin‑resistant Enterococcus (VRE) infections: active against strains resistant to vancomycin, aiding infection control.

Adverse reactions may vary in frequency and severity.

Common Side Effects: - Nausea: mild to moderate gastrointestinal upset. - Diarrhea: loose stools, occasionally watery. - Headache: transient cranial discomfort. - Vomiting: occasional emesis. - Metallic taste: altered taste perception. - Rash: mild skin erythema.

Serious or Rare Side Effects: - Thrombocytopenia: significant drop in platelet count, requiring monitoring. - Anemia: reduced red blood cell levels, potentially causing fatigue. - Leukopenia: lowered white blood cell count, increasing infection risk. - Peripheral neuropathy: nerve pain or sensory changes, may be irreversible. - Serotonin syndrome: risk when combined with serotonergic agents. - Lactic acidosis: rare metabolic disturbance with high morbidity.

Clinicians should consider several safety measures before initiating therapy.

- Renal impairment: adjust monitoring as renal function may affect drug clearance. - Hepatic impairment: use caution; liver dysfunction can alter metabolism. - Hematologic monitoring: perform regular blood counts to detect myelosuppression. - Concomitant serotonergic drugs: avoid or monitor closely due to serotonin syndrome risk. - Pregnancy & lactation: safety not established; weigh benefits against potential risks. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Linezolid may interact with several medication classes.

Major Interactions (Avoid): - Serotonergic agents (SSRIs, SNRIs, MAO inhibitors): risk of serotonin syndrome. - MAO inhibitors: potential hypertensive crisis. - Rifampin: induces metabolism, reducing linezolid exposure. - Anticoagulants (warfarin): may increase INR, enhancing bleeding risk. - Ethanol: may potentiate central nervous system depression.

Moderate Interactions (Monitor Closely): - NSAIDs: additive effect on bleeding risk. - Anticonvulsants (phenytoin, carbamazepine): may lower linezolid levels. - Digoxin: possible increase in serum concentration. - Oral contraceptives: monitor for reduced efficacy. - Immunosuppressants (cyclosporine): may require dose adjustment.